Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/175991
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBergamino Sirvén, Milana-
dc.contributor.authorPernas, Sònia-
dc.contributor.authorCheang, Maggie C. U.-
dc.date.accessioned2021-04-06T12:54:05Z-
dc.date.available2021-04-06T12:54:05Z-
dc.date.issued2021-02-09-
dc.identifier.urihttp://hdl.handle.net/2445/175991-
dc.description.abstractThe rapidly evolving landscape of immuno-oncology (IO) is redefining the treatment of a number of cancer types. IO treatments are becoming increasingly complex, with different types of drugs emerging beyond checkpoint inhibitors. However, many of the new drugs either do not progress from phase I-II clinical trials or even fail in late-phase trials. We have identified at least five areas in the development of promising IO treatments that should be redefined for more efficient designs and accelerated approvals. Here we review those critical aspects of IO drug development that could be optimized for more successful outcome rates in all cancer types. It is important to focus our efforts on the mechanisms of action, types of response and adverse events of these novel agents. The use of appropriate clinical trial designs with robust biomarkers of response and surrogate endpoints will undoubtedly facilitate the development and subsequent approval of these drugs. Further research is also needed to establish biomarker-driven strategies to select which patients may benefit from immunotherapy and identify potential mechanisms of resistance.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cancers13040691-
dc.relation.ispartofCancers, 2021, vol. 13, num. 4-
dc.relation.urihttps://doi.org/10.3390/cancers13040691-
dc.rightscc by (c) Bergamino Sirvén et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationCàncer-
dc.subject.classificationMarcadors bioquímics-
dc.subject.otherCancer-
dc.subject.otherBiochemical markers-
dc.titleLights and Shadows in Immuno-Oncology Drug Development-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-03-25T08:43:33Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid33572060-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
cancers-13-00691.pdf4.91 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons